patient numbers required for clinical study , page-24

Bocman

My view on PRR is that in about 12-18 months time subject to credible phase IIb data the SP could be substantilly higher.

Should the data not be good, ie. substantially better than the very limited data available so far then PRR will be back below 1c.

PRR desparately needs orphan drug status b/c without it even good phase IIb data will not make it attractive to a pharma partner due to core patent expiry in 2014.

Remember that as a general rule a big pharma spends as much on market launch than it does on a pivotal phase III trial.

I think the EU may have longer on the patents (2018?) but this by itself is not long enough if CVAC can only make it to the market in 2014.

I only hold a very small amount due to the risks here.